Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies

被引：0
作者：
Campbell, R. Keith
Cobble, Michael E.
Reid, Timothy S.
Shomali, Mansur E.
机构：
来源：
JOURNAL OF FAMILY PRACTICE | 2010年 / 59卷 / 09期
关键词：
GLUCAGON-LIKE PEPTIDE-1; BETA-CELL FUNCTION; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; HUMAN GLP-1 ANALOG; INSULIN-SECRETION; GLYCEMIC CONTROL; PARALLEL-GROUP; METFORMIN THERAPY; GLUCOSE-TOLERANCE; CONTROLLED-TRIAL;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：S5 / S9
页数：5
相关论文
共 47 条
[31]   Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study [J].
Moretto, Thomas J. ;
Milton, Denai R. ;
Ridge, Terry D. ;
MacConell, Leigh A. ;
Okerson, Ted ;
Wolka, Anne M. ;
Brodows, Robert G. .
CLINICAL THERAPEUTICS, 2008, 30 (08) :1448-1460
[32]   GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans [J].
Näslund, E ;
Bogefors, J ;
Skogar, S ;
Grybäck, P ;
Jacobsson, H ;
Holst, JJ ;
Hellström, PM .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1999, 277 (03) :R910-R916
[33]   Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [J].
Nathan, David M. ;
Buse, John B. ;
Davidson, Mayer B. ;
Ferrannini, Ele ;
Holman, Rury R. ;
Sherwin, Robert ;
Zinman, Bernard .
DIABETES CARE, 2009, 32 (01) :193-203
[34]   Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers [J].
Nauck, MA ;
Heimesaat, MM ;
Behle, K ;
Holst, JJ ;
Nauck, MS ;
Ritzel, R ;
Hüfner, M ;
Schmiegel, WH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) :1239-1246
[35]   PRESERVED INCRETIN ACTIVITY OF GLUCAGON-LIKE PEPTIDE-1 [7-36 AMIDE] BUT NOT OF SYNTHETIC HUMAN GASTRIC-INHIBITORY POLYPEPTIDE IN PATIENTS WITH TYPE-2 DIABETES-MELLITUS [J].
NAUCK, MA ;
HEIMESAAT, MM ;
ORSKOV, C ;
HOLST, JJ ;
EBERT, R ;
CREUTZFELDT, W .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :301-307
[36]   Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study [J].
Nauck, Michael ;
Frid, Anders ;
Hermansen, Kjeld ;
Shah, Nalini S. ;
Tankova, Tsvetalina ;
Mitha, Ismail H. ;
Zdravkovic, Milan ;
During, Maria ;
Matthews, David R. .
DIABETES CARE, 2009, 32 (01) :84-90
[37]   Unraveling the Science of Incretin Biology [J].
Nauck, Michael A. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (06) :3-10
[38]  
Peterson GE, 2009, J FAM PRACTICE, V58, pS21
[39]   Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients [J].
Toft-Nielsen, MB ;
Damholt, MB ;
Madsbad, S ;
Hilsted, LM ;
Hughes, TE ;
Michelsen, BK ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08) :3717-3723
[40]  
TURNER RC, 1995, DIABETES, V44, P1249
12345